How to Register a New Drug with NMPA in China: A Step-by-Step 2026 Guide

China’s pharmaceutical market, valued at approximately RMB 2.3 trillion (USD 317 billion) in 2025, is the world’s second-largest drug market and growing at 5-7% annually — outpacing both the US (3-4%) and EU (2-3%). For foreign pharmaceutical companies, China represents a critical growth opportunity, but accessing the market requires navigating a registration process administered by the National Medical Products Administration (NMPA) that is among the most demanding in the world in terms of clinical data requirements, review timelines, and post-approval compliance obligations.

This guide provides a comprehensive step-by-step walkthrough for foreign pharmaceutical companies seeking to register a new drug (化学药品新药 or 创新药) with the NMPA in 2026. The focus is on chemical new drugs (Class 1 innovative drugs), though relevant differences for biological products and traditional Chinese medicines are noted where applicable.

Understanding NMPA Drug Classification

The NMPA classifies chemical drugs into five registration categories, each with different data requirements and review pathways:

For foreign pharmaceutical companies developing innovative drugs, Class 1 registration is the primary pathway. For drugs already approved in the US, EU, or Japan, the Class 5 pathway allows the NMPA to leverage existing overseas clinical data through a bridging strategy, substantially reducing the time and cost of Chinese registration.

The NMPA Drug Registration Process: 7 Key Steps

Step 1: Pre-Submission Strategy and Gap Analysis (Months 1-3)

Before submitting any application, conduct a comprehensive gap analysis comparing your existing global clinical and quality data package against NMPA requirements. Key considerations:

• Clinical data bridging: The NMPA accepts multi-regional clinical trial (MRCT) data that includes Chinese patient populations. If your global trials did not include Chinese sites, determine whether a bridging study (with 80-120 Chinese patients) will suffice or whether a full Phase III study in China is required.
• Quality standards alignment: Chinese Pharmacopoeia (ChP) standards differ in some specifications from USP, EP, or JP. Identify gaps in impurity profiling, dissolution testing, or stability data that require supplemental studies.
• CMC requirements: The NMPA requires manufacturing site compliance with Good Manufacturing Practice (GMP) standards. Foreign sites must pass an NMPA GMP inspection (on-site or remote) before drug product can be imported for commercial sale.
• Regulatory classification: Confirm your product’s NMPA classification (Class 1-5). An incorrect classification can add 6-12 months to the process when the NMPA’s Center for Drug Evaluation (CDE) reclassifies the submission.

Engage a regulatory affairs consultant or law firm with NMPA drug registration experience at this stage. The cost of this engagement (typically USD 50,000-150,000 for a full gap analysis) is a high-ROI investment that prevents costly submission rejections later.

Step 2: Communication with CDE — Pre-IND and Pre-NDA Meetings (Months 3-6)

The CDE offers formal communication channels that foreign applicants should use proactively:

• Pre-IND meeting (临床试验前会议): Recommended for Class 1 drugs. Submit a meeting request with a briefing package covering the proposed clinical development plan, non-clinical data summary, and chemistry, manufacturing, and controls (CMC) overview. The CDE provides written feedback within 60 working days, clarifying data requirements and trial design expectations.
• Pre-NDA meeting (上市申请前会议): Conducted after clinical trials are complete but before the formal marketing authorization application. Use this meeting to confirm that your submission package addresses all CDE concerns and to agree on post-approval commitments.
• Communication frequency: The CDE encourages 2-3 formal communications per drug development program. Foreign sponsors can communicate in English (with CDE providing Chinese responses), though submitting documents in Chinese accelerates review by 2-4 weeks.

Step 3: Clinical Trial Application (CTA/IND) Submission (Months 6-7)

The submission of an Investigational New Drug (IND) application to conduct clinical trials in China follows a 60-working-day silent approval process under the 2020 Drug Administration Law amendments. Key submission components:

• Non-clinical pharmacology and toxicology data package
• Clinical study protocol (Phase I, II, or III as applicable)
• Investigator’s brochure
• CMC data including drug substance and drug product specifications, stability data, and manufacturing process description
• GMP compliance documentation for manufacturing facilities

The CDE reviews the submission within 60 working days. If no questions or objections are raised within this period, the IND is deemed approved and clinical trials may commence. If the CDE issues questions, the applicant has 20 working days to respond; the 60-day clock resets upon response submission.

Rejection rate: Approximately 15-20% of IND applications receive a clinical hold on first review, most commonly due to inadequate non-clinical safety data or unclear clinical trial designs. Pre-IND meetings reduce the first-review rejection rate to below 5%.

Step 4: Clinical Trial Execution (Months 7-24+)

Clinical trials in China must be conducted at CDE-qualified clinical trial centers. As of 2026, China has over 1,300 qualified clinical trial centers, with major concentrations in Beijing, Shanghai, Guangzhou, Chengdu, and Wuhan. Trial registration must be completed on the Chinese Clinical Trial Registry (ChiCTR) before enrollment begins.

Key considerations for foreign sponsors:

• Contract Research Organizations (CROs) — Most foreign sponsors engage a China-based CRO to manage site selection, ethics committee approvals (which are local, not central), patient enrollment, and regulatory reporting. Leading CROs include WuXi AppTec (LabCorp collaboration), IQVIA China, and Tigermed.
• Patient enrollment: China’s vast patient population allows rapid enrollment for most indications, but certain rare diseases may require 12-18 months for adequate enrollment. CDE offers expedited review pathways (突破性治疗药物) for serious conditions with unmet medical need.
• Ethics committee approval: Each trial site requires independent ethics committee (EC) approval. While the 2020 reforms introduced a centralized EC review mechanism for multi-site trials, local EC approvals still take 2-4 months on average.
• Safety reporting: China requires expedited reporting of suspected unexpected serious adverse reactions (SUSARs) within 7 days for fatal/life-threatening events and 15 days for other serious events, matching ICH E2B(R3) standards. Non-compliance with safety reporting timelines is the most common CDE inspection finding.

Step 5: New Drug Application (NDA) Submission (Months 24-27)

Upon completion of clinical trials, submit the New Drug Application (NDA) through the CDE’s electronic submission system. The NDA dossier must follow ICH Common Technical Document (CTD) format (M4) with the following modules:

• Module 1: Administrative information and prescribing information (in Chinese)
• Module 2: CTD summaries — Quality, Nonclinical, and Clinical overviews and summaries
• Module 3: Quality — Drug substance and drug product CMC data
• Module 4: Nonclinical study reports
• Module 5: Clinical study reports

The NMPA accepts submissions in Chinese or English (with Chinese summary required for Module 1). However, submitting the full dossier in Chinese reduces review time by approximately 20-30% because CDE reviewers do not need to translate sections internally.

Step 6: CDE Review and Approval (Months 27-39)

The NMPA’s standard NDA review timeline is 200 working days (approximately 10 months), but complex applications typically extend to 12-18 months due to CDE questions (补充资料通知) and the applicant’s response time.

CDE review process:

• Preliminary review (5 working days): Administrative completeness check
• Technical review (120 working days): Full scientific evaluation by CDE review teams, including clinical, non-clinical, and CMC specialists
• Supplementary information request: If CDE identifies data gaps, a formal question letter is issued. The applicant has 80 working days to respond, and the review clock restarts from the date of response submission.
• On-site or remote GMP inspection: For foreign manufacturing sites, the NMPA may conduct an on-site or remote GMP inspection. Remote inspections (initiated during COVID and retained as an option) take 3-5 days; on-site inspections require 4-8 weeks of scheduling lead time.
• Final decision (20 working days): After technical review and inspection are complete, the NMPA issues its approval decision.

Accelerated pathways available in 2026:

• Breakthrough therapy designation (突破性治疗药物): For drugs addressing serious conditions with no effective treatment. Shaves 3-6 months off standard review.
• Priority review (优先审评): For drugs on the CDE’s priority review list. Review timeline is 130 working days vs. 200 for standard review.
• Conditional approval (附条件批准): For drugs that demonstrate significant therapeutic advantage. Approval is granted based on surrogate endpoints, with post-market confirmatory studies required.

Step 7: Post-Approval Compliance and Lifecycle Management (Months 39+)

NMPA approval is not the end of the regulatory process. Post-approval obligations include:

• Post-market surveillance: Submit periodic safety update reports (PSURs) every 6 months for the first 2 years, then annually for years 3-5.
• GMP maintenance: NMPA GMP certificates are valid for 5 years and subject to renewal inspection. Any manufacturing changes (site, process, equipment) require prior notification or approval depending on change significance.
• Variation management: Post-approval changes are classified into three tiers: major changes (require prior NMPA approval), moderate changes (require notification with 60-day review), and minor changes (record-keeping only). Improper variation management is a leading cause of regulatory enforcement actions against foreign pharmaceutical companies in China.
• Re-registration (再注册): Drug registration certificates are valid for 5 years and require renewal within 6 months of expiry. Re-registration requires demonstration of continued marketing in the Chinese market (at least one commercial batch every 3 years).
• Drug pricing and reimbursement: NMPA approval does not guarantee National Reimbursement Drug List (NRDL) inclusion. NRDL listing is a separate process managed by the National Healthcare Security Administration (NHSA) involving annual price negotiations that have reduced average drug prices by 40-70% in recent years.

NMPA Drug Registration Quick-Reference Checklist

Follow this ordered checklist to ensure you complete every phase of the NMPA drug registration process without missing critical submissions or deadlines.

1. Conduct pre-submission gap analysis — Compare your existing global data package against NMPA requirements, identifying gaps in clinical data (Chinese patient populations), quality standards (ChP vs. USP/EP), and GMP compliance documentation.
2. Request pre-IND meeting with CDE — Prepare and submit a briefing package covering your clinical development plan, non-clinical data, and CMC overview. Use CDE feedback to finalize your clinical trial design and submission strategy.
3. Submit IND application — Compile the full IND package including non-clinical data, clinical protocols, investigator’s brochure, CMC data, and GMP documentation. Prepare for potential CDE questions within the 60-working-day review window.
4. Engage China-based CRO and select trial sites — Select a CRO with relevant therapeutic area expertise. Identify and contract with 5-15 CDE-qualified clinical trial centers, obtaining local ethics committee approvals.
5. Complete clinical trials with Chinese patient populations — Execute the clinical trial protocol meeting CDE requirements. Submit protocol amendments if needed. Manage safety reporting per Chinese SUSAR timelines.
6. Submit NDA in CTD format — Compile Module 1-5 dossiers following ICH CTD format with Chinese-language Module 1 and Chinese summaries for other modules. Include the final clinical study reports.
7. Respond to CDE review questions — Monitor for CDE supplementary information requests and respond within the 80-working-day window. If a GMP inspection is scheduled, prepare manufacturing site documentation and arrange logistics.
8. Manage post-approval lifecycle — Submit PSURs on schedule, maintain GMP compliance, manage variations and changes appropriately, and prepare for re-registration within 5 years. Begin NRDL strategy discussions with the NHSA.

Common Pitfalls in NMPA Drug Registration

Inadequate Chinese clinical data. The most common reason for NMPA rejection is insufficient evidence of drug safety and efficacy in Chinese populations. Even drugs approved by the US FDA and EMA are not guaranteed NMPA approval without Chinese-specific clinical data. The NMPA’s ethnic sensitivity analysis requirements mean that drugs with significant ethnic differences in metabolism (e.g., CYP2D6 substrates, warfarin, certain oncology drugs) may require substantially larger Chinese clinical programs.

Underestimating review timelines. Foreign pharmaceutical companies often budget 24-30 months for NMPA review and are surprised when the actual timeline extends to 36-48 months. The CDE’s 200-working-day standard review timeline is a best-case scenario; most applications experience at least one round of supplementary questions, adding 4-8 months to the process.

Inadequate CMC data for ChP compliance. The Chinese Pharmacopoeia requires specific impurity profiling (including Chinese-specific impurities), dissolution testing methods, and stability conditions (40°C/75% RH for accelerated stability, versus the 40°C/75% RH or 30°C/65% RH used in ICH Q1A). Foreign applicants who submit USP-compliance-only CMC data often face extended review cycles or outright rejection.

Neglecting GMP inspection lead time. NMPA GMP inspections for foreign manufacturing sites can take 6-12 months to schedule from the initial inspection request. Plan for this lead time in your registration timeline, and consider requesting a remote GMP inspection if your product qualifies.

Ignoring NRDL pricing implications. Many foreign pharmaceutical companies achieve NMPA approval only to discover that their product is commercially unviable at the prices required for NRDL listing. Develop pricing and access strategy in parallel with the registration process, ideally starting NRDL health economic modeling 12-18 months before expected NMPA approval.

Where to Go From Here

The first step for any foreign pharmaceutical company considering NMPA registration is a gap analysis comparing your existing development data against NMPA requirements. This analysis should be conducted by a regulatory affairs team with specific NMPA drug registration experience — not a general pharmaceutical consultant. The cost of a thorough gap analysis (USD 50,000-150,000) is negligible compared to the cost of a failed or substantially delayed submission. For drugs not yet in clinical development, incorporating China into your global clinical trial strategy from the start — by including Chinese trial sites in your MRCT program — is the single most effective way to accelerate Chinese registration and reduce development costs.

Last updated: July 2026. NMPA regulatory framework reflects the Drug Administration Law (2019, effective 2020) and implementing regulations in effect as of mid-2026. Always consult current NMPA guidance documents and a qualified regulatory affairs professional before initiating a submission.